Viskase Companies, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Thomas Dale Davis
- Full Time Employees
- 1,582
- Sector
- Consumer Cyclical
- Industry
- Packaging & Containers
- Address
- 333 East Butterfield Road Lombard IL United States of America 60148-5679
- IPO Date
- Feb 15, 1984
- CIK
- 0000727510
- Website
- viskase.com
- Similar Companies
- Business
- Enzon Pharmaceuticals, Inc. Enzon Pharmaceuticals, Inc. (OTCQX: ENZN) is a biopharmaceutical company positioned as a public company acquisition vehicle that seeks to become an acquisition platform to more fully utilize its net operating loss carryforwards and enhance stockholder value. Founded in 1981 and headquartered in Cranford, New Jersey, the company previously focused on the development and commercialization of therapeutics to treat life-threatening diseases, including cancer, through its proprietary PEGylation technologies such as Customized Linker Technology, which employs chemical linkers to attach polyethylene glycol (PEG) to injectable therapeutics for controlled release or permanent linkage to improve efficacy, reduce dosing frequency, and minimize side effects; historically, it marketed specialty pharmaceutical products like ONCASPAR (pegaspargase for acute lymphoblastic leukemia), ADAGEN (pegademase bovine for severe combined immunodeficiency disease), DEPOCYT (cytarabine liposome injection for lymphomatous meningitis), and ABELCET (amphotericin B lipid complex for invasive fungal infections), while generating royalties from licensed PEGylated products including PEG-INTRON, PEGASYS, and MACUGEN. The company conducts no significant operations at present, having sold its specialty pharmaceutical business to Sigma-Tau Pharmaceuticals in 2010 for approximately $327 million; in recent developments, Enzon entered into a definitive merger agreement with Viskase Companies, Inc. (OTC Pink Limited: VKSC) announced in 2025, with an amendment on October 24, 2025, adjusting ownership to 45% for Enzon stockholders and 55% for Viskase stockholders in the combined entity following Viskase's merger into a wholly owned subsidiary of Enzon in an all-stock transaction.
Enzon Pharmaceuticals (OTCMKTS:ENZN) Shares Pass Above 200 Day Moving Average – Here’s What Happened
Enzon Announces Completion of the Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
Enzon Announces Reverse Stock Split
Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock
Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger
Enzon and Viskase Announce Amendment to Merger Agreement
Enzon and Viskase Enter into Merger Agreement
7 Undervalued Biotech Stocks to Buy Before They Boom
Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon's CFO, to Assume Position of CEO and Remain CFO